Clinical trial · Interventional
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion
NCT01448759CI-TRIAL-00017645ALCOOTAXcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluation of plasma alcohol
- timeFrame
- One year
- description
- Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule. * Patient with bitherapy are eligible only if the taxane is the first infusion. * All type of tumor. * Age\>18 years old. * Signed written informed consent. Exclusion Criteria: * Patient under 18. * Patient with bitherapy, if docetaxel or paclitaxel is not administered first. * Patient deprived of liberty.
References
Publications (0)
Data not yet available
No reference posted for this study.